If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
337
results.
Updated on
21/08/2026 [07:27:00]
Results 325 to 337 of 337
Absstract of: EP4763997A1
The present invention relates to biomarkers capable of diagnosing various brain and nervous system diseases, and a method of providing information for diagnosing brain and nervous system diseases using the same. According to the present invention, it is possible to diagnose, at an early stage, the onset of a brain and nervous system disease or the likelihood of developing the disease or diagnose the progress or prognosis of the disease or the therapeutic effect against the disease, by measuring the expression level of the biomarker protein of the present invention or a gene encoding the same in the aqueous humor of the eye.
Absstract of: WO2024235879A1
The invention relates to a nasal fluid sample obtained from a subject comprising the marker protein(s) β amyloid (Aβ), phosphorylated Tau (pTau) and/or total Tau (tTau). The invention further relates to a nasal fluid sample comprising the marker protein(s) Aβ, pTau and/or tTau for use in a method for the aid in diagnosis of neurodegenerative diseases and the use of a nasal fluid sample comprising the marker protein(s) Aβ, pTau and/or tTau for the aid in diagnosis of a neurodegenerative disease. The invention further relates to a method for the aid in diagnosis of a neurodegenerative disease in a subject/individual.
Absstract of: WO2024235880A1
The invention relates to an in vitro method for diagnosing or predicting a neurodegenerative disease in a subject, said method comprising A/T/N classification in nasal secretion samples obtained from said subject. Said A/T/N classification subsequently may be used, but is not limited to, the diagnosis of Alzheimer's disease (AD), the diagnosis of SNAP or the exclusion of AD.
Absstract of: US2025123294A1
In one aspect, a method for screening an individual for head and neck cancer, which comprising: acquiring a saliva sample from the individual, analyzing the saliva sample to detect one or more of HPVs and at least one of a phenotypic biomarker, a regulatory biomarker, a microbiome-derived biomarker, and a metabolomic biomarker dysregulated due to HPV infection, wherein detection of both of the HPV and at least one of said biomarkers indicates the individual is at risk of head and neck cancer.
Absstract of: WO2024227045A1
The present disclosure provides methods and kits for identifying and treating individuals at risk of or suffering from disease such as a neurological condition or disease. In general, detection or measurement of one or more biomarkers, such as neurofilament light chain (NfL), and combinations thereof with assays of the present disclosure, assists in the identification of disease such as neurological disease. The present disclosure also provides methods for selecting patients for treatment of neurological disease.
Absstract of: US2025003990A1
0000 Disclosed herein are improved assays, cartridges, kits, and methods of use thereof for detecting biomarkers, e.g., one or more biomarkers of brain injury, including, without limitation, biomarkers of acquired brain injury (ABI), such as, traumatic brain injury (TBI). The improved assays described herein may aid in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head (e.g., TBI) by detecting levels of a biomarker, such as UCH-L1, GFAP, or a combination thereof, in samples taken from a subject (e.g., a human subject).
Absstract of: CN122256501A
0001 本发明涉及生物医药领域，具体涉及偏头痛诊断的生物标志物、试剂盒及其应用。本发明所述的偏头痛疾病相关的生物标志物包括COL4A2，同时还包括MMP‑14、LCAT、ADAMTS13和CPXM2中的任意一种或多种的组合。本发明基于临床健康对照和偏头痛患者的蛋白质组学数据，应用生信分析和机器学习等方法，深入挖掘对偏头痛疾病诊断最有预警价值的蛋白质组合，并在扩大样本的临床队列中进行验证，为新发现的生物标志物的临床转化提供良好前景，同时也为后续机制研究奠定基础。
Absstract of: CN122255284A
本发明涉及生物技术领域，具体的，本发明公开了一种酪氨酸碘化修饰PP2A蛋白的单克隆抗体、制备方法及应用。本发明通过制备酪氨酸碘化修饰的PP2A蛋白抗原肽，免疫兔制备单克隆抗体，并利用噬菌体展示技术淘选、表达载体扩增和ELISA筛选，最终获得一株能有效识别靶标的单克隆抗体R004。该抗体在免疫组织化学、细胞免疫荧光和蛋白免疫印迹中均表现出良好的灵敏度和特异性。本发明筛选得到的单克隆抗体可以用于PP2A蛋白催化亚基307位酪氨酸碘化修饰的检测中，为肿瘤诊断、抗肿瘤和神经疾病药物的研发提供支持。
Absstract of: WO2020168254A1
A method of determining the potency of an immune cell is described. The method includes the steps of contacting an immune cell with an effective amount of a cell exosome and detecting the amount of a cytokine produced by the immune cell. Kits for assaying immune cell potency are also described. Potency assays are important for satisfying the FDA requirements for new biological agents, such as immunotherapeutic cells. Methods of using potent immune cells as an immunotherapeutic treatment are described.
Absstract of: CN122259816A
本发明涉及一种用于脑类器官药物测试的实时监测方法和系统，包括如下步骤：S1、进行脑类器官的制备与预培养；S2、微电极阵列芯片与反应微室的准备：将芯片安装于反应微室中，所述反应微室中央设计花瓣式流体槽结构，中心为样本腔体，外围的花瓣槽道与入口和出口流道相连；S3、脑类器官的装载与固定：在下层微电极阵列电极中心放置脑类器官后放置上层微电极阵列芯片，使脑类器官被夹持在上下电极之间，保证接触充分但不造成压伤；S4、药物灌注与电生理实时监测：将药物沿流道进入花瓣式流体槽并扩散至反应腔体，实时记录脑类器官电信号变化；S5、进行系统清洗与复用。
Absstract of: GB2702871A
Automatically validating quality data of at least a digital slide 110, 118 scanned by an optical device. The slide is identified 122 with metadata 120 and object detection 128 locates the stained core. The data from the stained core is aligned into a standard form 132 and evaluated against a threshold 134. The stained core is compared to a control core 136 to generate the validation output 138 which is transmitted to a downstream device 140. Generating the validation output may use a stain statistical model 142 to compute the threshold value and may include cross validating 170 a positive control core 164 to confirm. Further a reliability of the validation output may be obtained. This requires configuring one or more optical device parameters comprising a magnification level and a scanning speed of the optical device as a function of the stained core of interest and the positive control core. Figure 1
Nº publicación: KR20260094342A 22/06/2026
Applicant:
엘브이아이에스리게인엘피
Absstract of: WO2025038979A1
Material compositions and/or methods useful for the prophylaxis and/or treatment of protein depletion (proteinopenia) are provided, including material compositions that retains native function of a peptide/protein while limiting and/or preventing amyloid formation and/or aggregation of said peptide/protein. Material compositions and formulations for enhancing peptide/protein solubility, stability, circulation time, receptor interaction, brain penetrance, CSF half-life, facilitating peptide/protein synthesis and purification are also provided.
BOPI
Electronic site
